1. Home
  2. LEXX vs COHN Comparison

LEXX vs COHN Comparison

Compare LEXX & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • COHN
  • Stock Information
  • Founded
  • LEXX 2004
  • COHN 1999
  • Country
  • LEXX Canada
  • COHN United States
  • Employees
  • LEXX N/A
  • COHN N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • LEXX Health Care
  • COHN Finance
  • Exchange
  • LEXX Nasdaq
  • COHN Nasdaq
  • Market Cap
  • LEXX 19.6M
  • COHN 17.9M
  • IPO Year
  • LEXX N/A
  • COHN N/A
  • Fundamental
  • Price
  • LEXX $0.83
  • COHN $10.03
  • Analyst Decision
  • LEXX Strong Buy
  • COHN
  • Analyst Count
  • LEXX 1
  • COHN 0
  • Target Price
  • LEXX $7.00
  • COHN N/A
  • AVG Volume (30 Days)
  • LEXX 146.6K
  • COHN 7.1K
  • Earning Date
  • LEXX 07-11-2025
  • COHN 08-04-2025
  • Dividend Yield
  • LEXX N/A
  • COHN 10.00%
  • EPS Growth
  • LEXX N/A
  • COHN N/A
  • EPS
  • LEXX N/A
  • COHN N/A
  • Revenue
  • LEXX $525,923.00
  • COHN $84,171,000.00
  • Revenue This Year
  • LEXX $0.62
  • COHN N/A
  • Revenue Next Year
  • LEXX $14.19
  • COHN N/A
  • P/E Ratio
  • LEXX N/A
  • COHN N/A
  • Revenue Growth
  • LEXX 29.95
  • COHN N/A
  • 52 Week Low
  • LEXX $0.82
  • COHN $6.10
  • 52 Week High
  • LEXX $4.38
  • COHN $11.52
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 31.77
  • COHN 73.60
  • Support Level
  • LEXX $0.93
  • COHN $7.97
  • Resistance Level
  • LEXX $1.05
  • COHN $10.21
  • Average True Range (ATR)
  • LEXX 0.07
  • COHN 0.32
  • MACD
  • LEXX -0.00
  • COHN 0.20
  • Stochastic Oscillator
  • LEXX 14.14
  • COHN 80.43

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: